Exicure (XCUR) Expected to Announce Quarterly Earnings on Friday

Exicure (NASDAQ:XCUR) will likely be announcing its results before the market opens on Friday, August 7th. Analysts expect Exicure to announce earnings of ($18.60) per share and revenue of $1.6440 million for the quarter.

Exicure (NASDAQ:XCUR) last announced its earnings results on Friday, May 29th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.31.

Exicure Price Performance

XCUR stock opened at $1.51 on Thursday. The company has a market cap of $9.62 million, a price-to-earnings ratio of -0.97 and a beta of 3.65. The company has a fifty day moving average price of $2.20 and a 200 day moving average price of $3.36. Exicure has a 12 month low of $1.42 and a 12 month high of $9.48.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.